Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Concordance for Parkinson's disease in twins: A 20-year update.

Goldman SM, Marek K, Ottman R, Meng C, Comyns K, Chan P, Ma J, Marras C, Langston JW, Ross GW, Tanner CM.

Ann Neurol. 2019 Feb 20. doi: 10.1002/ana.25441. [Epub ahead of print]

PMID:
30786044
2.

Therapies to Slow, Stop, or Reverse Parkinson's Disease.

Foltynie T, Langston JW.

J Parkinsons Dis. 2018;8(s1):S115-S121. doi: 10.3233/JPD-181481.

3.

Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic.

Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C.

J Parkinsons Dis. 2019;9(1):207-219. doi: 10.3233/JPD-181373.

4.

Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease.

Zafar F, Valappil RA, Kim S, Johansen KK, Chang ALS, Tetrud JW, Eis PS, Hatchwell E, Langston JW, Dickson DW, Schüle B.

NPJ Parkinsons Dis. 2018 Jun 15;4:18. doi: 10.1038/s41531-018-0054-4. eCollection 2018.

5.

Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration.

Quansah E, Peelaerts W, Langston JW, Simon DK, Colca J, Brundin P.

Mol Neurodegener. 2018 May 24;13(1):28. doi: 10.1186/s13024-018-0260-x. Review.

6.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Kluge AF, Patane MA, Van Drie JH, Wang C, McElligott D, Kesicki EA, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2018 Jun;558(7710):E1. doi: 10.1038/s41586-018-0111-5.

PMID:
29769713
7.

MPTP-induced parkinsonism: an historical case series.

Nonnekes J, Post B, Tetrud JW, Langston JW, Bloem BR.

Lancet Neurol. 2018 Apr;17(4):300-301. doi: 10.1016/S1474-4422(18)30072-3. Epub 2018 Mar 13. No abstract available. Erratum in: Lancet Neurol. 2018 Mar 27;:.

PMID:
29553378
8.

Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm.

Langston JW, Wiley JC, Tagliati M.

NPJ Parkinsons Dis. 2018 Feb 23;4:5. doi: 10.1038/s41531-018-0041-9. eCollection 2018. Review.

9.

LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.

Lee K, Nguyen KD, Sun C, Liu M, Zafar F, Saetern J, Flierl A, Tetrud JW, Langston JW, Dickson D, Schüle B.

J Parkinsons Dis. 2018;8(1):93-100. doi: 10.3233/JPD-171237.

PMID:
29480226
10.

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.

Michaelides MR, Kluge A, Patane M, Van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R, Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA, Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA.

ACS Med Chem Lett. 2017 Dec 13;9(1):28-33. doi: 10.1021/acsmedchemlett.7b00395. eCollection 2018 Jan 11.

11.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2017 Oct 5;550(7674):128-132. doi: 10.1038/nature24028. Epub 2017 Sep 27. Erratum in: Nature. 2018 May 16;:.

12.

Parkinson's disease associated with pure ATXN10 repeat expansion.

Schüle B, McFarland KN, Lee K, Tsai YC, Nguyen KD, Sun C, Liu M, Byrne C, Gopi R, Huang N, Langston JW, Clark T, Gil FJJ, Ashizawa T.

NPJ Parkinsons Dis. 2017 Sep 5;3:27. doi: 10.1038/s41531-017-0029-x. eCollection 2017.

13.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

14.

The MPTP Story.

Langston JW.

J Parkinsons Dis. 2017;7(s1):S11-S19. doi: 10.3233/JPD-179006. Review. No abstract available.

15.

Parkinson's disease is ready for precision medicine.

Sherer TB, Frasier MA, Langston JW, Fiske BK.

Per Med. 2016 Sep;13(5):405-407. doi: 10.2217/pme-2016-0052. Epub 2016 Aug 9. No abstract available.

16.

Is PARKIN parkinsonism a cancer predisposition syndrome?

Schüle B, Byrne C, Rees L, Langston JW.

Neurol Genet. 2015 Oct 15;1(4):e31. doi: 10.1212/NXG.0000000000000031. eCollection 2015 Dec.

17.

Erratum: Multisystem Lewy body disease and the other parkinsonian disorders.

Langston JW, Schüle B, Rees L, Nichols RJ, Barlow C.

Nat Genet. 2016 Apr;48(4):473. doi: 10.1038/ng0329-473b. No abstract available.

PMID:
27023778
18.

Multisystem Lewy body disease and the other parkinsonian disorders.

Langston JW, Schüle B, Rees L, Nichols RJ, Barlow C.

Nat Genet. 2015 Dec;47(12):1378-84. doi: 10.1038/ng.3454. Erratum in: Nat Genet. 2016 Apr;48(4):473.

PMID:
26620112
19.

Comparative genomic hybridization solves a 14-year-old PARKIN mystery.

Schüle B, Hatchwell E, Eis PS, Langston JW.

Ann Neurol. 2015 Oct;78(4):663-4. doi: 10.1002/ana.24478. Epub 2015 Aug 29. No abstract available.

PMID:
26179350
20.

When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.

Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW.

Neurology. 2015 Aug 4;85(5):404-12. doi: 10.1212/WNL.0000000000001807. Epub 2015 Jul 2.

21.

LRRK2 dephosphorylation increases its ubiquitination.

Zhao J, Molitor TP, Langston JW, Nichols RJ.

Biochem J. 2015 Jul 1;469(1):107-20. doi: 10.1042/BJ20141305. Epub 2015 May 5.

22.

Defining the minimally effective dose and schedule for parenteral hydrogen sulfide: long-term benefits in a rat model of hindlimb ischemia.

Langston JW, Toombs CF.

Med Gas Res. 2015 Apr 16;5:5. doi: 10.1186/s13618-015-0027-1. eCollection 2015.

23.

Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease.

Furlong M, Tanner CM, Goldman SM, Bhudhikanok GS, Blair A, Chade A, Comyns K, Hoppin JA, Kasten M, Korell M, Langston JW, Marras C, Meng C, Richards M, Ross GW, Umbach DM, Sandler DP, Kamel F.

Environ Int. 2015 Feb;75:144-50. doi: 10.1016/j.envint.2014.11.002. Epub 2014 Nov 21.

24.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

25.

Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.

Flierl A, Oliveira LM, Falomir-Lockhart LJ, Mak SK, Hesley J, Soldner F, Arndt-Jovin DJ, Jaenisch R, Langston JW, Jovin TM, Schüle B.

PLoS One. 2014 Nov 12;9(11):e112413. doi: 10.1371/journal.pone.0112413. eCollection 2014.

26.

Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms.

Riley BE, Gardai SJ, Emig-Agius D, Bessarabova M, Ivliev AE, Schüle B, Alexander J, Wallace W, Halliday GM, Langston JW, Braxton S, Yednock T, Shaler T, Johnston JA.

PLoS One. 2014 Aug 29;9(8):e102909. doi: 10.1371/journal.pone.0102909. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e115081. Schüle, Birgit [corrected to Schüle, Birgitt].

27.

Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.

Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K.

Genet Med. 2014 Aug;16(8):644-5. doi: 10.1038/gim.2014.55. No abstract available.

28.

Peptidoglycan recognition protein genes and risk of Parkinson's disease.

Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Sandler DP, Langston JW, Tanner CM.

Mov Disord. 2014 Aug;29(9):1171-80. doi: 10.1002/mds.25895. Epub 2014 May 17.

29.

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B.

Neurobiol Dis. 2014 Feb;62:381-6. doi: 10.1016/j.nbd.2013.10.013. Epub 2013 Oct 19.

30.

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.

Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA.

PLoS One. 2013 Aug 23;8(8):e71634. doi: 10.1371/journal.pone.0071634. eCollection 2013.

31.

Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease.

Ahn TB, Langston JW, Aachi VR, Dickson DW.

Am J Neurodegener Dis. 2012;1(1):49-59. Epub 2012 Apr 18.

32.

Genetic modification of the association of paraquat and Parkinson's disease.

Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM.

Mov Disord. 2012 Nov;27(13):1652-8. doi: 10.1002/mds.25216. Epub 2012 Oct 8.

33.

Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants.

Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P; Chinese Parkinson Study Group (CPSG).

Parkinsonism Relat Disord. 2012 Sep;18(8):958-63. Epub 2012 Jun 2.

PMID:
22658533
34.

Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage.

Mak SK, Huang YA, Iranmanesh S, Vangipuram M, Sundararajan R, Nguyen L, Langston JW, Schüle B.

Stem Cells Int. 2012;2012:140427. doi: 10.1155/2012/140427. Epub 2012 Apr 10.

35.

α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.

Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O.

Neurobiol Dis. 2012 Aug;47(2):258-67. doi: 10.1016/j.nbd.2012.04.009. Epub 2012 Apr 19.

36.

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium.

Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687.

37.

Head injury, α-synuclein Rep1, and Parkinson's disease.

Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM.

Ann Neurol. 2012 Jan;71(1):40-8. doi: 10.1002/ana.22499.

38.

Journal of Parkinson's Disease--an excellent first year and a new sister.

Brundin P, Langston JW.

J Parkinsons Dis. 2012;2(2):77. doi: 10.3233/JPD-2012-12901. No abstract available.

PMID:
23933746
39.

SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.

Byers B, Cord B, Nguyen HN, Schüle B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, Palmer TD.

PLoS One. 2011;6(11):e26159. doi: 10.1371/journal.pone.0026159. Epub 2011 Nov 16.

40.

Solvent exposures and Parkinson disease risk in twins.

Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM.

Ann Neurol. 2012 Jun;71(6):776-84. doi: 10.1002/ana.22629. Epub 2011 Nov 14.

41.

Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

Jenner P, Langston JW.

Mov Disord. 2011 Nov;26(13):2316-23. doi: 10.1002/mds.23926. Epub 2011 Sep 23. Review.

PMID:
21953831
42.

Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.

Shchepinov MS, Chou VP, Pollock E, Langston JW, Cantor CR, Molinari RJ, Manning-Boğ AB.

Toxicol Lett. 2011 Nov 30;207(2):97-103. doi: 10.1016/j.toxlet.2011.07.020. Epub 2011 Aug 10.

PMID:
21906664
44.

Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.

Marras C, Schüle B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, Meaney C, Klein C, Wadia PM, Lim SY, Chuang RS, Zadikof C, Steeves T, Prakash KM, de Bie RM, Adeli G, Thomsen T, Johansen KK, Teive HA, Asante A, Reginold W, Lang AE.

Neurology. 2011 Jul 26;77(4):325-33. doi: 10.1212/WNL.0b013e318227042d. Epub 2011 Jul 13. Erratum in: Neurology. 2011 Oct 11;77(15):1501. Schuele, B [corrected to Schüle, B].

45.

Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease.

Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N.

PLoS Genet. 2011 Jun;7(6):e1002141. doi: 10.1371/journal.pgen.1002141. Epub 2011 Jun 23.

46.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
47.

Rotenone, paraquat, and Parkinson's disease.

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW.

Environ Health Perspect. 2011 Jun;119(6):866-72. doi: 10.1289/ehp.1002839. Epub 2011 Jan 26.

48.

Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication.

Mak SK, Tewari D, Tetrud JW, Langston JW, Schüle B.

J Parkinsons Dis. 2011;1(2):175-83. doi: 10.3233/JPD-2011-11025.

PMID:
23934919
49.

Journal of Parkinson's disease.

Brundin P, Langston JW.

J Parkinsons Dis. 2011;1(1):1. doi: 10.3233/JPD-2011-10022. No abstract available.

PMID:
23934894
50.

Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease.

Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW.

Mov Disord. 2010 Oct 30;25(14):2296-303. doi: 10.1002/mds.23348.

PMID:
20976736

Supplemental Content

Loading ...
Support Center